Cargando…

P1195: A PROSPECTIVE STUDY OF TARGETED SEQUENTIAL IMMUNOTHERAPY. IN PATIENTS WITH RELAPSED REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA.

Detalles Bibliográficos
Autores principales:	Guo, Yuelu, Hu, Kai, Ke, Xiaoyan, Xu, Teng, Feng, Shaomei, Zheng, Peihao, MA, Lixia, Yang, Fan, Shi, Hui, Deng, Biping, Rui, Liu, Fu, Zhonghua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430905/ http://dx.doi.org/10.1097/01.HS9.0000971676.94450.1b

Ejemplares similares

P1168: DURABLE REMISSION AFTER SEQUENTIAL CD19/20 CAR T-CELL “CAKE-ICING” THERAPY OCCURRED IN REFRACTORY/RELAPSED DLBCL
por: Zheng, Peihao, et al.
Publicado: (2023)

Genetic landscapes and curative effect of CAR T-cell immunotherapy in patients with relapsed or refractory DLBCL
por: Shi, Hui, et al.
Publicado: (2022)

The Autologous Hematopoietic Stem Cells Transplantation Combination-Based Chimeric Antigen Receptor T-Cell Therapy Improves Outcomes of Relapsed/Refractory Central Nervous System B-Cell Lymphoma
por: Xue, Fei, et al.
Publicado: (2022)

PB2326: OUTCOMES OF ANTI-CANCER THERAPY IN PATIENTS WITH PROGRESSIVE REFRACTORY/RELAPSED B-CELL LYMPHOMA DURING SEVERE CORONAVIRUS DISEASE 2019 (COVID-19): A REAL-WORLD STUDY FROM CHINA
por: Su, Guoai, et al.
Publicado: (2023)

P1173: EARLY ADMINISTRATION OF POLATUZUMAB VEDOTIN AS BRIDGING CD19-SPECIFIC CHIMERIC ANTIGEN RECEPTOR T CELL THERAPY IS AN EFFECTIVE STRATEGY TO IMPROVE SURVIVAL IN PATIENTS WITH R/R B-CELL LYMPHOMA
por: Yang, Fan, et al.
Publicado: (2023)

PB2101: A PROSPECTIVE INVESTIGATION INTO THE TIMING AND STATUS OF BCMA-CART IN SECONDARY PLASMA CELL LEUKEMIA
por: Guo, Yuelu, et al.
Publicado: (2023)

PB2333: CAR-T CELL THERAPY IS A EXCELLENT STRATEGY FOR R/R B-NHL
por: Rui, Liu, et al.
Publicado: (2023)

Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory/relapsed B-cell lymphoma
por: Yang, Fan, et al.
Publicado: (2022)

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma
por: Armand, Philippe, et al.
Publicado: (2019)

The role of pembrolizumab in relapsed/refractory primary mediastinal large B-cell lymphoma
por: Tomassetti, Sarah, et al.
Publicado: (2019)

Sequential different B-cell antigen–targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphoma
por: Liu, Ying, et al.
Publicado: (2022)

Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing
por: Gao, Fan, et al.
Publicado: (2021)

Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170
por: Zinzani, Pier Luigi, et al.
Publicado: (2023)

Dual Immunotherapy Adds Value in Relapsed/Refractory Hodgkin Lymphoma
por: Hallam, Simon
Publicado: (2018)

Checkpoint inhibitor immunotherapy during pregnancy for relapsed–refractory Hodgkin lymphoma
por: Evens, Andrew M., et al.
Publicado: (2022)

Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy
por: Randall, Michael P., et al.
Publicado: (2023)

Mediastinal Choriocarcinoma Masquerading as Relapsed Hodgkin Lymphoma
por: Lam, Selay, et al.
Publicado: (2011)

Sequential immunotherapy in a patient with primary refractory Hodgkin lymphoma and novel mutations
por: Greil, Richard, et al.
Publicado: (2018)

Checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients?
por: Balzarotti, Monica, et al.
Publicado: (2020)

Mediastinal cryptococcosis masquerading as therapy-refractory lymphoma
por: Wong, Matthew, et al.
Publicado: (2010)

High-dose chemotherapy followed by autologous stem cell transplantation for relapsed/refractory primary mediastinal large B-cell lymphoma
por: Aoki, T, et al.
Publicado: (2015)

PB2309: OUTCOMES OF 22 PATIENTS WITH RELAPSED OR REFRACTORY PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA: SINGLE INSTITUTE EXPERIENCE
por: Tumyan, Gayane, et al.
Publicado: (2023)

P1195: A REAL WORLD EXPERIENCE OF COMBINED TREATMENT WITH ROMIDEPSIN AND AZACITIDINE IN PATIENTS WITH PERIPHERAL T-CELL LYMPHOMA.
por: Kalac, M., et al.
Publicado: (2022)

Cytopenia after chimeric antigen receptor T cell immunotherapy in relapsed or refractory lymphoma
por: Zhou, Jin, et al.
Publicado: (2022)

Erratum to checkpoint inhibitors in primary mediastinal B-cell lymphoma: a step forward in refractory/relapsing patients?
por: Balzarotti, Monica, et al.
Publicado: (2020)

Relapsed/Refractory Hodgkin Lymphoma
por: Sheikh, Semira, et al.
Publicado: (2018)

Chimeric Antigen Receptor-Modified T Cell Immunotherapy for Relapsed and Refractory Adult Burkitt Lymphoma
por: Wu, Jiaying, et al.
Publicado: (2022)

1195. "The Economic Impact of Antimicrobial Use for Surgical Prophylaxis: A Prospective Study
por: Gnanamani, James, et al.
Publicado: (2023)

Blinatumomab in Relapsed/Refractory Burkitt Lymphoma
por: Bohler, Jeanne, et al.
Publicado: (2022)

Management of relapsed-refractory diffuse large B cell lymphoma
por: Raut, Lalit S., et al.
Publicado: (2014)

Mediastinal Single Nodal Relapse of a Nasal Nk/T cell Lymphoma
por: Rhee, Kyoung Hoon, et al.
Publicado: (2007)

A PET Radiomics Model to Predict Refractory Mediastinal Hodgkin Lymphoma
por: Milgrom, Sarah A., et al.
Publicado: (2019)

The COX-2-1195AA Genotype Is Associated with Diffuse-Type Gastric Cancer in Korea
por: Shin, Woon Geon, et al.
Publicado: (2012)

EP1195: COVID-19 INFECTION AND BREAKTHROUGH INFECTION IN POST LIVER TRANSPLANT PATIENTS
por: Moein, Hamid-Reza, et al.
Publicado: (2022)

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
por: An, Lihong, et al.
Publicado: (2022)

Decitabine combined with RDHAP regimen in relapsed/refractory diffuse large B cell lymphoma
por: Kong, Xiaoshuang, et al.
Publicado: (2023)

Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
por: Chen, Runzhe, et al.
Publicado: (2015)

Belinostat for Relapsed or Refractory Peripheral T-Cell Lymphoma
por: Hood, Katelyn, et al.
Publicado: (2016)

New agents in relapsed/refractory Hodgkin's lymphoma()
por: Biasoli, Irene, et al.
Publicado: (2017)

The role of tazemetostat in relapsed/refractory follicular lymphoma
por: von Keudell, Gottfried, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5vsd6opcg12cnffuntv08a3uc9